Buy, hold, sell: Resmed, Goodman Group, Westpac shares

S&P/ASX 200 Index (ASX: XJO) shares closed 0.24% lower at 8,604.2 points on Tuesday.

Let’s check out 3 ASX 200 shares with new ratings from analysts on The Bull this week.

Resmed CDI (ASX: RMD)

The Resmed share price finished 1.3% higher at $28 yesterday.

Mark Gardner from MPC Markets has a hold rating on this ASX 200 healthcare share.

Gardner explained his view: 

ResMed remains a high quality respiratory care business. Concerns about the impact of GLP-1 weight loss drugs have weighed on sentiment, although recent analysis suggests the big undiagnosed sleep apnoea market still provides a long runway for device demand.

The company continues to benefit from a strong mask and device portfolio, but investors were disappointed management left its fiscal year 2026 outlook unchanged after a solid third quarter result.

Our hold recommendation balances the quality of the franchise against near term uncertainty around margins, competition and investor expectations.

Goodman Group (ASX: GMG)

The Goodman share price closed 0.32% higher at $31.20 on Tuesday.

Tony Locantro from Alto Capital has a sell rating on the ASX 200’s biggest real estate share by market capitalisation.

Locantro says Goodman is seeking to capitalise on artificial intelligence (AI) while maintaining large exposure to logistics infrastructure. 

Data centres represent about 73% of the company’s pipeline, and total work in progress is expected to reach about $18 billion this month.

Locantro discussed his sell rating on Goodman shares:

While the long term outlook for digital infrastructure remains highly attractive, investor enthusiasm surrounding AI and data centres has driven a substantial re-rating in the share price.

With significant growth expectations already reflected in the valuation, future returns may become increasingly dependent on flawless execution of large scale projects.

Given the strong share price performance and elevated market expectations, the risk-reward balance supports taking profits at current levels, in our view.

Westpac Banking Corp (ASX: WBC)

The Westpac share price finished 0.29% lower at $34.71 yesterday.

Damien Nguyen from Morgans has a sell rating on this ASX 200 bank share.

Nguyen said: 

Revenue growth appears constrained by a competitive mortgage market and subdued business lending conditions.

The bank has made meaningful progress on its strategic simplification agenda, shedding non-core businesses and improving its risk and compliance foundations.

The pathway to sustainable outperformance remains unclear. In our view, the recent share price doesn’t offer a sufficient margin of safety in a challenging banking environment.

We see the risk–reward equation as unfavourable at recent levels.

The post Buy, hold, sell: Resmed, Goodman Group, Westpac shares appeared first on The Motley Fool Australia.

More reading

• Morgans rates these ASX shares as buys with up to 55% upside
• Why there could be hidden value in REITs right now
• 3 high-quality Australian shares I’d buy with $10,000
• Down 28% in a year, should I buy the dip on Resmed shares right now?
• Why these ASX blue-chip shares are strong buys right now

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goodman Group and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.